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analysis with more advanced RT technique is needed to 
assess the future role of RT in orbital tumors. 
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Purpose or Objective: Breast cancer patients receiving post-
operative radiotherapy (RT) experience adverse effects and 
general fatigue is one of them. Although it is often not severe 
enough to interrupt the course of RT, it negatively affects 
quality of life. Some Japanese herbal medicines such as TJ-41 
(Hochu-ekki-to) are effective for fatigue and are often used 
in daily practice. The purpose of this study is to assess 
radiation-induced fatigue (RIF) in detail and investigate the 
effect of Japanese herbal medicine. 
 
Material and Methods: Breast cancer patients who received 
post-operative RT and agreed to answer a patient self-
reporting questionnaire (FACIT-F; Functional Assessment of 
Chronic Illness Therapy) were eligible for this study. We 
excluded patients who were receiving chemotherapy 
concurrently. RIF was defined as fatigue which occurred 
during the period of radiotherapy and there were no causes 
for the fatigue other than the radiotherapy. The FACIT-F 
questionnaire was answered before RT, at one week after the 
beginning of RT, at the end of RT and one month after the 
end of RT. We prescribed TJ-41 to the RIF patients during the 
radiotherapy. We defined as responders the patients who 
experienced improvements in RIF and hoped for further 
prescription. 
 
Results: Fifty-two patients were enrolled for this study. RIF 
was observed in 24 (46 %) patients. On univariate analysis, 
the statistically significant predictor of RIF was the score of 
FACIT-F before RT. TJ-41 was administered to 9 patients and 
8 of them (89 %) were responders. 
 
Conclusion: RIF was common in breast cancer patients 
receiving post-operative RT and TJ-41 was effective for the 
RIF patients and improved their quality of life. However, 
these results may lack objectivity and the study was 
conducted with no placebo group. Improvement in objectivity 
of the assessment and a comparative study will be needed. 
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Purpose or Objective: Hyperthermia is a powerful 
radiosensitizer for treatment of superficial tumors. Several 
trials showed an advantage of combining radiotherapy with 
hyperthermia in terms of both local tumor control and overall 
survival. The purpose of this study is to evaluate both 
efficacy and toxicity of radiotherapy-hyperthermia (RT-HT) in 
the treatment of superficial recurrent and metastatic tumors 
in patients previously or not previously irradiated. 
 
Material and Methods: In our Institution twenty-three 
patients (mean age 71,4 years; range: 51-88) with 
histologically confirmed superficial recurrent/metastatic 
tumors were enrolled: 11 breast carcinoma, 6 head&neck 
cancer, 2 malignant melanoma, 2 sarcomas, 1 uterine 
adenocarcinoma and 1 hepatocarcinoma. Patients underwent 
radiotherapy treatment using 3D-conformal radiotherapy 
(8/23) or Helical Tomotherapy (15/23). External beam 
radiotherapy was delivered in 6-27 fractions of 1.8-5 Gy for a 
total dose of 20-57.5 Gy (mean external dose: 41 Gy). 
Prescribed dose was established taken into account, of the 
previous radiation doses, in previously irradiated patients, 
Karnofsky performance status and patient compliance. 
Hyperthermia treatment was performed with an 
electromagnetic superficial applicator operating at the 
frequency of 434 MHz. HT session was delivered once/twice 
weekly during the period of external radiotherapy, 1-2 hours 
after radiotherapy, to a mean total of 5 treatments [range: 
1-9 sessions]. Termocouples were used to evaluate 
temperature distribution map. Average, maximum and 
minimum temperature parameters were recorded during 
hyperthermia treatment. The treatment goal was to reach 
40- 42°C in > 90% (T90) of measured points for a duration of 
60 minutes. Acute and late toxicity was evaluated according 
to the CTCAE criteria. Local control was assessed after the 
end of the treatment on the basis of the RECIST Criteria.  
 
Results: During hyperthermia treatment the median 
temperature reached was 40.5 °C [range: 39 – 42.9°C]. 
During the radiotherapy in association with hyperthermia 2 
pts (10%) had G3 toxicity and one of these interrupted the 
treatment. One pt had acute cutaneous toxicity ≥ G3 at 1 
month. No pts had toxicity ≥ G2 at 3 and 6 months. No 
toxicity was observed at 12 months. The mean follow-up was 
10 months (range 3-22 months). Four pts (17%) had a 
complete response (CR), 11 pts ( 48%) had a partial response 
(PR),7 pts (30%) had a stable disease, (SD) and only 1 pt (4%) 
had progression disease (PD) and subsequently died. The 
Local control rate was 95%. Univariate analysis showed that 
Tmean,Tmax, Tmin,T90 parameters were not associated with 
local control rate.  
 
Conclusion: Radio-hyperthermia can result in an effective 
approach, particularly in previously irradiated patients or in 
radio-resistant tumors. Our results show that Radio-
Hyperthermia is an useful combined treatment with a good 
local control rate and a very high patient compliance.  
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Purpose or Objective: The purpose of this study is to 
evaluate the decrease in pain of patients treated with low-
dose radiation therapy in osteoarthritis. 
 
Material and Methods: From April 2015 to September 2015, 
11 patients (10 female and 1 men) were treated with low 
dose radiotherapy for pain control. All patients were 
refractory to conventional therapy prior to irradiation.  
13 joints (6 bursitis and 7 arthrosis): 4 trochanteritis, 5 
knees, 1 left thumb rhizarthrosis, 2 metacarpophalangeal 
joint and 1 right epicondylitis were treated.  
The median age was 69 years (range 46-89) with a median 
follow-up period of 3 months (range 0-6). Painful status was 
measured by visual analogue scale (VAS), with a median pre-
treatment value of VAS= 7(range 4-9).  
The radiotherapy dose of 6 Gy was delivered in 6 alternate 
days fractions of 1 Gy per fraction. In those patient with no 
pain relive post-treatment with VAS of or above 6 a second 
course of radiotherapy was proposed.  
The second RT series started 8 weeks after the first RT 
series.  
 
Results: The analysis was performed before the treatment 
and at the last follow-up. With a median VAS = 5 (range 0-8) 
7 patients achieved pain relief, 3 patients underwent a 
second course of radiotherapy with identical dose, and 1 
patient showed no change in pain. Daily requirements of 
analgesic were removed of reduced in 5 patients, subjective 
pain perception of response to irradiation evaluated at time 
of last visit regarding pre-treatment status was considered as 
“better” by 73% of patient. No patients presented acute or 
late complications attribute to radiation therapy. 
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Conclusion: RT is highly effective for refractory degenerative 
joint diseases. Prognostic factors for outcome can be 
established. Due to minimal side effects and low costs, RT 
represents an excellent treatment compared to conventional 
methods of treatment and surgery in the chronic disease. 
This study confirms by objective criteria the anti-
inflammatory efficacy of low dose RT  
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Purpose or Objective: Hospital General Universitario 
Gregorio Marañon has a long-standing tradition of IOeRT 
(Intraoperative electron Radiation Therapy), with over 1600 
procedures in its 20 year history. Since december 2013, a 
minituarized linear accelerator (LIAC) started to operate in 
our center. We describe the 22 months technical and clinical 
experience with LIAC in our consolidated IOeRT program.  
 
Material and Methods: A review of technical and surgical 
parameters of IOeRT procedures using LIAC was performed 
from December 2013 to October 2015,  
 
Results: From december 2013 to october 2015, 222 
procedures in 185 patients were performed (200 procedures 
with LIAC, 22 transported to a fixed lineal accelerator). 
Cancer types treated were 64 oligorecurrences / 
oligometastases, 34 breast cancers, 44 rectal cancers, 42 
sarcomas, 6 pancreatic adenocarcinomas, 4 esophageal 
neoplasms and 6 other cancer types. The treated anatomic 
sites included 100 cases in pelvis, 40 in abdomen, 25 in limbs, 
34 in breast and 1 in thorax. Relevant operational data 
included 39 days with more than 2 procedures in the same 
working day (22% of total days). Six different applicator sizes 
were selected (range 4-10) with 4 beveled ends (range 0-45). 
Selected energies ranged from 6 to 12. 
 
Conclusion: LIAC is a versatile technology able to be 
incorporated to expert IORT institutions promoting efficient 
action with operative benefits in terms of availability of 
IOeRT components for cancer patients. 
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Purpose or Objective: There has been a rapid growth in the 
number of immuno- and immunoradiotherapy trials over the 
last few decades. Long term durable responses occur, but 
only in a subset of patients. As yet no accurate method of 
identifying those patients most likely to benefit has been 
identified. The factors behind non-response are unclear but 
may include 1) inherent characteristics of the tumour, 2) 
factors influencing immunogenicity such as tumour burden 
and previous treatments and 3) clinical trial design By 
performing a cross sectional analysis of registered clinical 
trials investigating agents thought to stimulate T-cells we 
aimed to detect trends in these factors. In particular we 
aimed to assess the extent to which trials sought to develop 
and identify novel biomarkers of response to immunotherapy. 
 
Material and Methods: A pubmed literature search was 
conducted to establish a list of known T cell checkpoints, co-
stimulatory receptors, ligands, and the antibodies targeting 
these. These search terms were entered into clinical 
trials.gov on October 11, 2014. Study details were 
downloaded as datasets for review by two independent 
assessors. 
 
Results: We identified a total of 350 trials of 
immunomodulatory antibodies targeting PD-1, CTLA4, PD-L1, 
PD-L2, LAG3, B7-H3, CD137, OX40, CD27 and GITR. A 
longitudinal analysis by trial registration date shows a steady 
increase in the number of trials using immunostimulatory 
antibodies As some cancer types are thought to be more 
immunogenic, we looked at the spread of trials by cancer 
type. Unsurprisingly, melanoma trials represent the largest 
proportion, but there has been a shift towards testing 
immunostimulatory antibodies in cancers that are considered 
less immunogenic with a significant increase in trials in NSLC 
when comparing trials registered between 2000 and 2007 and 
those registered between 2008 and 2014. Only 39% of trials 
measured a dynamic immune endpoint as a specified 
outcome. T and B cell number or function were the most 
common markers analysed. However there was a significant 
increase in the measurement of PD-L1 expression in recent 
years.  
 
Conclusion: This analysis provides comprehensive data on the 
rapid growth of immunotherapy trials and highlights that 
despite the multiplicity and variability of potential dynamic 
biomarkers available, there has been a poor uptake. Whilst 
the future of immunotherapy is not in doubt, biomarkers are 
essential to understand the considerable lack of response and 
help guide further trial efforts. 
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Purpose or Objective: New targeted therapies (nTTs) are 
increasingly used in virtually every type of cancer. On the 
other hand radiation therapy (RT) is frequently applied in the 
curative and palliative setting of cancer treatment, 
confronting clinicians more and more with the problem, 
weather a previously initiated nTT-therapy could be 
continued during RT. The aim of this systematic literature 
analysis was to evaluate the toxicity of concomitant 
application of RT with nTTs in a qualitative descriptive 
manner.  
 
Material and Methods: Clinical studies comprising 
concomitant application of RT with EGFR-, VEGFR-, HDAC-, 
proteasom-, BRAF-, m-Tor- or immune-checkpoint-inhibitors 
were eligible. Using fixed search terms 215 publications were 
identified including more than 6000 patients. Forty-eight 
studies analyzed combinations of nTTs with ZNS-RT including 
1164 patients, 45 with head and neck-RT including 2390 
patients, 59 with thoracic RT including 1647 patients, 33 with 
abdominal RT and 30 with pelvic RT including 492 and 1008 
patients respectively.  
 
Results: In most cases combined application produced no 
additional toxicity or a slight increase of the already known 
toxicity profile. Scarcely, however, combination of RT with 
nTTs resulted in serious side effects. These toxicities 
comprised tracheo-bronchial fistulas or GI-bleeding for 
combinations of thoracic or abdominal/pelvic RT with VEGF-
receptor-inhibitors, recall phenomena in combination of RT 
with tyrosinkinase inhibitors e.g. erlotinib and severe 
mucositis, dermatitis or paraplegia (case report) when 
combining RT with ipilimumab. For the majority of these 
